Abstract：Objective: To elucidate the function of miR-193a in HCC. Methods: The expression levels of miR-193a and Wilms' tumor-1 (WT1) were detected by quantitative real Time-polymerase chain Reaction (qRT-PCR) assay. In addition, miR-193a expression was also investigated in MHCC97H,HCCLM3,Huh7 and LO2 cell lines. Moreover, the HCC proliferation was examined through cell counting Kit-8 (CCK-8) assay after miR-193a overexpression or inhibition. Tumor growth of HCC was observed via xenograft tumor formation assay. The relationship between miR-193a and WT1 was verified by the dual-Luciferase assay. Results: Downregulation of miR-193a whereas upregulation of WT1 were identified in HCC, which predicted a worse prognosis in HCC patients. Meanwhile, miR-193a was significantly decreased in LO2 cell lines compared with MHCC97H,HCCLM3,Huh7 cell lines. Low miR-193a expression HCC patients showed severer TMN stage and presence of lymph node metastasis. Furthermore, it was found that miR-193a mimic suppressed cell proliferation by inhibiting WT1. miR-193a also inhibited tumor growth of HCC. Conclusion: miR-193a suppressed tumorigenesis of HCC by targeting WT1.
刘亚琪, 郑承红. MicroRNA-193a 通过靶向 WT1抑制肝细胞癌发生的机制研究[J]. 河北医学, 2021, 27(1): 1-4.
LIU Yaqi, et al. Mechanism of MicroRNA-193a Suppressing the Tumorigenesis of Hepatocellular Carcinoma Through Targeting WT1. HeBei Med, 2021, 27(1): 1-4.
[1] Alqahtani A, Khan Z, Alloghbi A, et al. Hepatocellular carcinoma: molecular mechanisms and targeted therapies[J]. Medicina (Kaunas), 2019, 55(9) pii: E526. [2] Khordadmehr M, Shahbazi R, Sadreddini S, et al. miR-193: a new weapon against cancer[J].Cell Physiol,2019,234(10):16861~16872. [3] Xie F, Hosany S, Zhong S, et al. MicroRNA-193a inhibits breast cancer proliferation and metastasis by downregulating WT1[J]. PLoS One, 2017,12(10):e0185565. [4] Angelico G, Santoro A, Straccia P, et al. Diagnostic and prognostic role of WT1 immunohistochemical expression in uterine carcinoma: a systematic review and meta-analysis across All endometrial carcinoma histotypes [J]. Diagnostics (Basel), 2020,10(9):E637. [5] Zhang Y, Yan WT, Yang ZY, et al. The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism[J]. Int Biol Sci, 2020,16(8):1474~1480. [6] Tsuboi A, Hashimoto N, Fujiki F, et al. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma[J]. Cancer Immunol Immunother, 2019,68(2):331~340. [7] Zhang W, Qian S, Yang G, et al. MicroRNA-199 suppresses cell proliferation, migration and invasion by downregulating RGS17 in hepatocellular carcinoma[J]. Gene, 2018,15(659): 22~28. [8] Liu X, Min S, Wu N, et al. miR-193a-3p inhibition of the slug activator PAK4 suppresses non-small cell lung cancer aggressiveness via the p53/Slug/L1CAM pathway[J]. Cancer Lett,2019,10(447):56~65. [9] Chen ZM, Yu Q, Chen G, et al. MiR-193a-3p inhibits pancreatic ductal adenocarcinoma cell proliferation by targeting CCND1[J]. Cancer Manag Res, 2019,27(11):4825~4837. [10] Pekow J, Meckel K, Dougherty U, et al. miR-193a-3p is a key tumor suppressor in ulcerative colitis-associated colon cancer and promotes carcinogenesis through upregulation of IL17RD[J]. Clin Cancer Res, 2017,23(17):5281~5291. [11] Hastie ND. Wilms' tumour 1 (WT1) in development, homeostasis and disease[J]. Development, 2017,144(16):2862~2872. [12] Hong L, Zhao X, Shao X, et al. MiR-590 regulates WT1 during proliferation of G401 cells[J]. Mol Med Rep,2017, 16(1): 247~253.
2021, Vol. 27 
冀公网安备13080202000677号